Detalhe da pesquisa
1.
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Blood
; 126(13): 1565-74, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26254443
2.
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Mol Cancer Ther
; 13(10): 2315-27, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25053825
3.
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Oncotarget
; 5(14): 5637-50, 2014 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25026298
4.
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Mol Cancer Ther
; 13(5): 1142-54, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24435446